Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Bristol Pushes Pedal To Metal In Immuno-Oncology Combo Testing

Executive Summary

Bristol's early development lead exec Mike Burgess explains how the company is embracing adaptive trial design to rapidly test combinations of immuno-oncology drugs old and new, plus targeted agents.


Related Content

How Immuno-Oncology Is Turning Biomarker Development On Its Head
Bristol Should Have Opdivo First-Line Lung Cancer Data In Weeks
Roche's Guide To Success In Oncology
Novartis' Signature speeds up clinical trials


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst